All Updates

All Updates

icon
Filter
Partnerships
Foundation Medicine and Syndax Pharmaceuticals partner to develop diagnostic for AML patients
Precision Medicine
Sep 4, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Funding
Operant AI raises USD 10 million in Series A funding to boost runtime protection
Next-gen Cybersecurity
Yesterday
Funding
Aembit raises USD 25 million in Series A funding to advance IAM solutions
Identity & Access Management
Yesterday
Product updates
Saviynt launches Intelligence Suite for identity security
Identity & Access Management
Yesterday
Geographic expansion
Partnerships
FarmWise partners with RDO Equipment Co. to expand AI-powered weeding technology for vegetable growers
Smart Farming
Yesterday
Management news
Alberta Food Security Inc. receives USD 5 million order for indoor farming technology
Vertical Farming
Yesterday
Partnerships
AutoStore enhances microfulfilment offering with new grid capabilities and multi-temperature solution
Logistics Tech
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Generative AI Applications
Yesterday
Precision Medicine

Precision Medicine

Sep 4, 2024

Foundation Medicine and Syndax Pharmaceuticals partner to develop diagnostic for AML patients

Partnerships

  • Foundation Medicine has partnered with Syndax Pharmaceuticals to develop a diagnostic tool for acute myeloid leukemia (AML) patients with an NPM1 mutation.

  • The partnership aims to identify AML patients with NPM1 mutations and to develop a companion diagnostic based on the FoundationOne Heme platform. This could potentially increase access to targeted therapies such as Syndax's drug revumenib for AML patients with this specific mutation. If approved, it could potentially be the first next-generation sequencing companion diagnostic for hematologic neoplasms. Syndax has also agreed to support Foundation Medicine's regulatory approval process for this diagnostic assay.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.